Active Recombinant Human AKT3, GST-tagged

Cat.No. : AKT3-1365H
Product Overview : Recombinant full-length human AKT3 was expressed by baculovirus in Sf9 insect cells using a N-terminal GST tag.
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : AKT 3 or Protein Kinase B γ (PKBγ) is a serine/threonine kinase that is a member of the AKT family. AKT 3 is activated in cells exposed to diverse stimuli such as hormones, growth factors, and extracellular matrix components.AKT 3 phosphorylates and regulates the function of many cellular proteins involved in processes that include cellular metabolism, survival/apoptosis, and proliferation. Recent evidence indicates that AKT 3 is frequently overexpressed in many types of human cancers including breast and prostate.
Source : Sf9 Cells
Species : Human
Tag : GST
Form : Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, 25% glycerol.
Bio-activity : 206 nmol/min/mg
Molecular Mass : ~85 kDa
Protein length : Full length
Purity : >90%
Applications : Kinase Assay, Western Blot
Storage : Store at –70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. Avoid freeze/thaw cycles.
Concentration : 0.1μg/μl
Gene Name : AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) [ Homo sapiens ]
Official Symbol : AKT3
Synonyms : AKT3; v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); RAC-gamma serine/threonine-protein kinase; PKBG; PRKBG; RAC gamma; PKB gamma; RAC-gamma serine/threonine protein kinase; STK-2; PKB-GAMMA; RAC-gamma; RAC-PK-gamma; DKFZp434N0250;
Gene ID : 10000
mRNA Refseq : NM_001206729
Protein Refseq : NP_001193658
MIM : 611223
UniProt ID : Q9Y243
Chromosome Location : 1q44
Pathway : AKT phosphorylates targets in the cytosol, organism-specific biosystem; AKT phosphorylates targets in the nucleus, organism-specific biosystem; AKT-mediated inactivation of FOXO1A, organism-specific biosystem; Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem; Adaptive Immune System, organism-specific biosystem; Adipocytokine signaling pathway, organism-specific biosystem;
Function : ATP binding; nucleotide binding; protein binding; protein kinase activity; protein serine/threonine kinase activity;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (20)

Ask a question
What are the implications of AKT3 dysregulation? 02/10/2023

Dysregulation of AKT3 activity is associated with various human diseases, including cancer, diabetes, neurodegenerative disorders, and cardiovascular diseases. Overactivation of AKT3 can promote uncontrolled cell growth and survival, a hallmark of cancer. In contrast, reduced AKT3 activity is linked to insulin resistance and type 2 diabetes.

Is AKT3 exclusively expressed in certain cell types or can it be found in multiple cell types? 01/23/2023

AKT3 is not exclusively expressed in specific cell types and can be found in multiple cell types. While it is abundantly expressed in neuronal tissues and plays a role in brain development, AKT3 is also expressed in other cell types, including epithelial cells, endothelial cells, and immune cells.

Are there any known diseases or disorders associated with dysregulation of AKT3? 01/03/2023

Yes, dysregulation of AKT3 has been implicated in a variety of diseases and disorders. As mentioned earlier, genetic mutations in AKT3 are associated with diseases such as Proteus syndrome and megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Additionally, dysregulation of AKT3 has been observed in various types of cancer, including breast, ovarian, colorectal, and lung cancer, where it promotes cell survival, proliferation, and resistance to therapies. Altered AKT3 activity has also been implicated in neurological disorders such as autism spectrum disorder and epilepsy.

Are there any ongoing clinical trials targeting AKT3? 05/06/2022

Yes, there are ongoing clinical trials investigating AKT inhibitors that target the AKT pathway, which includes AKT3. These trials are evaluating the efficacy and safety of AKT inhibitors in various cancer types, such as breast, ovarian, lung, and prostate cancer.

Are there any drugs targeting AKT3 currently available? 03/14/2022

As of now, there are no FDA-approved drugs specifically targeting AKT3. However, there are several ongoing preclinical and clinical studies investigating the efficacy of AKT inhibitors that could potentially target AKT3 in various diseases, including cancer. Some of these compounds include MK-2206, AZD5363, GSK2141795, and ipatasertib.

What are the downstream targets of AKT3? 01/12/2021

AKT3 phosphorylates and modulates the activity of numerous downstream targets involved in cell survival and growth regulation. Examples include the anti-apoptotic protein Bcl-2, the mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK-3), and several transcription factors, such as forkhead box O (FOXO) and nuclear factor kappa B (NF-κB).

Is AKT3 expressed in all tissues of the body? 11/16/2020

AKT3 is expressed in a wide range of tissues but its expression levels may vary among different tissues. For instance, AKT3 is more abundantly expressed in the brain, heart, and skeletal muscles compared to other tissues. However, it is important to note that the expression levels of AKT3 can be dynamically regulated depending on cellular context, developmental stage, and environmental cues.

Can AKT3 inhibitors be used in combination with other cancer treatments? 02/18/2020

Yes, AKT3 inhibitors can potentially be used in combination with other cancer treatments to enhance their efficacy. Preclinical studies have shown that combining AKT inhibitors with chemotherapy drugs or targeted therapies can improve anti-tumor effects. For example, combining AKT inhibitors with HER2-targeted therapies has been explored in HER2-positive breast cancer. Additionally, AKT inhibitors may also sensitize tumors to radiation therapy. However, more research is needed to optimize the combination strategies and determine the most effective treatment regimens.

Can AKT3 inhibitors be used to treat other diseases besides cancer? 12/04/2019

AKT3 inhibitors primarily have been studied in the context of cancer treatment, but the AKT pathway is involved in various physiological and pathological processes beyond cancer. As a result, AKT inhibitors have been explored for potential therapeutic applications in other diseases.

Can AKT3 be regulated by other signaling pathways? 07/22/2019

Yes, AKT3 can be regulated by various signaling pathways apart from its canonical activation through growth factors. For example, AKT3 can be activated by insulin signaling, which plays a crucial role in glucose metabolism and cellular energy homeostasis. AKT3 can also be influenced by other pathways such as the AMP-activated protein kinase (AMPK) pathway, which regulates cellular energy status, and the Wnt pathway, which is involved in cell proliferation and differentiation.

Are there any genetic mutations associated with AKT3? 02/08/2019

Yes, genetic mutations in the AKT3 gene have been identified in rare human diseases. One well-known condition associated with AKT3 mutations is Proteus syndrome, a complex and highly variable disorder characterized by overgrowth of various tissues. AKT3 mutations are also found in a condition called megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH), which is characterized by overgrowth of the brain, abnormal brain development, and other features.

How is AKT3 activated? 02/04/2019

AKT3 is activated through a phosphorylation cascade. Upon stimulation by growth factors or other extracellular signals, phosphoinositide-dependent kinase-1 (PDK1) phosphorylates AKT3 at threonine 308. This partially activates AKT3. Full activation of AKT3 requires phosphorylation at serine 473, which is carried out by the mammalian target of rapamycin complex 2 (mTORC2).

Are there any known alternative splicing variants of AKT3? 10/22/2018

Yes, alternative splicing events can generate different isoforms of AKT3. One example is AKT3β, which lacks a portion of the N-terminal regulatory region compared to the full-length AKT3α isoform. These isoforms may have distinct functions and regulatory mechanisms, although further research is needed to fully understand their specific roles.

Are there any specific mutations or alterations in AKT3 that are associated with cancer? 09/04/2018

Yes, alterations in AKT3 have been identified in various types of cancer. These alterations include genetic mutations, gene amplifications, and overexpression of AKT3. For example, AKT3 mutations have been reported in certain types of human cancers, such as endometrial cancer and melanoma.

Is AKT3 involved in any cellular processes besides cell survival and growth? 06/23/2018

Yes, AKT3 is involved in a variety of cellular processes besides cell survival and growth. It plays a role in regulating cellular metabolism, including glucose uptake and lipid metabolism. AKT3 is also involved in cell migration and invasion, as well as the regulation of cell cycle progression and apoptosis. Additionally, AKT3 has been implicated in neuronal development and synaptic plasticity, playing a role in brain development and function.

Are there any known interactions between AKT3 and other proteins or signaling pathways? 05/19/2017

Yes, AKT3 interacts with a wide range of proteins and signaling pathways. It can interact with various upstream activators, such as PI3K, PDK1, and mTORC2, to be phosphorylated and activated. AKT3 can also interact with numerous downstream effectors, including mTOR, GSK3, FOXO transcription factors, and Bad, among others. Additionally, AKT3 can be regulated by cross-talk with other signaling pathways, such as MAPK, NF-κB, and Wnt signaling, which can modulate its activity and downstream functions.

Can AKT3 inhibition alone be sufficient for cancer treatment or is it often combined with other therapies? 08/03/2016

While AKT3 inhibition has shown promise as a potential cancer treatment strategy, it is often used in combination with other therapies. The AKT pathway is complex and interconnected with various cellular processes, and targeting only AKT3 may not be sufficient to fully inhibit AKT signaling in all contexts. Additionally, combination therapies can help overcome potential resistance mechanisms and enhance treatment efficacy. Therefore, AKT3 inhibitors are frequently investigated in combination with chemotherapy, targeted therapies, immunotherapy, or radiation therapy to determine the optimal treatment strategies for different cancer types.

Can AKT3 be therapeutically targeted in diseases? 05/20/2016

Yes, targeting AKT3 therapeutically is an active area of research, especially in the context of cancer treatment. Several AKT inhibitors are being developed and tested in preclinical and clinical studies with the aim of blocking AKT3-mediated signaling and inhibiting tumor growth. However, it is important to note that AKT is also essential for normal cellular functions, so the development of selective inhibitors that specifically target the disease-associated dysregulation of AKT3 without affecting normal AKT activity is crucial.

Can AKT3 be targeted therapeutically? 05/16/2016

AKT3 has been under investigation as a potential target for therapeutic intervention. Inhibitors of AKT3 and its upstream regulators are being developed to selectively inhibit aberrant AKT3 signaling in diseases such as cancer. However, more research is needed to fully understand the complexities of AKT3 signaling and improve the specificity and efficacy of AKT3-targeted therapies.

Are there any potential side effects or limitations associated with AKT3 inhibition? 04/30/2016

While AKT3 inhibitors show promise as potential therapeutics, they can also have side effects and limitations. AKT is crucial for normal cellular functions, so inhibiting its activity may affect normal physiological processes.

Customer Reviews (5)

Write a review
Reviews
03/25/2023

    I am confident that utilizing the AKT3 protein will empower me to uncover crucial insights into cellular mechanisms with precision.

    12/31/2022

      The AKT3 protein is an exceptional protein solution that exceeds expectations in terms of quality and suitability for my experimental requirements.

      12/22/2020

        Their expertise and guidance will undoubtedly prove valuable in overcoming hurdles and maximizing the potential of this protein in my research endeavors.

        07/29/2016

          In addition to its outstanding quality, the AKT3 protein comes with exceptional technical support from its manufacturer.

          02/01/2016

            Researchers can confidently rely on this high-quality protein to produce accurate and reproducible results, thereby accelerating their research progress

            Ask a Question for All AKT3 Products

            Required fields are marked with *

            My Review for All AKT3 Products

            Required fields are marked with *

            0

            Inquiry Basket

            cartIcon
            logo

            FOLLOW US

            Terms and Conditions        Privacy Policy

            Copyright © 2024 Creative BioMart. All Rights Reserved.

            Contact Us

            • /

            Stay Updated on the Latest Bioscience Trends